Last updated: 2026-09-08 08:58:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
MiNK Therapeutics, Inc. (INKT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $11.42, with a market capitalization of $59.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.48 to $16.98. This page covers its latest market performance, valuation, price trends and company information.
$59.40M | |
$11.16 | |
$221.55 | |
$4.56 | |
$11.23 | |
5.70K | |
14.41K | |
-- | |
$16.98 | |
$8.48 | |
-- | |
-- |
MiNK Therapeutics, Inc. (INKT) is trading at $11.48 in pre-market trading as of 2026-09-04 23:31:00, up 2.24% ($0.25) from the previous close of $11.23
Pre-market trading shows how investors are pricing INKT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, MiNK Therapeutics, Inc. (INKT) moved from $11.68 to $11.42, representing a decline of 2.19% ($0.26).
The stock traded between $10.82 and $11.80 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 6.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 34.6%
INKT is currently trading at $11.42, placing it 34.6% of the way from its 52-week low of $8.48 to its 52-week high of $16.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MiNK Therapeutics, Inc. (INKT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.